MedTrace Logo

Specific Immunotherapy With Recombinant Birch Pollen Allergen rBet v1-FV

NCT00266526 · Status: COMPLETED · Phase: PHASE2 · Type: INTERVENTIONAL

Last updated 2013-03-04

No results posted yet for this study

Summary

Specific immunotherapy with recombinant birch pollen allergen rBet v1-FV

Conditions

  • Birch Pollen Allergy

Interventions

BIOLOGICAL

Recombinant birch pollen

Sponsors & Collaborators

  • Allergopharma GmbH & Co. KG

    lead INDUSTRY

Principal Investigators

  • Annemie Narkus, M.D.

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
NONE
Model
PARALLEL

Eligibility

Min Age
18 Years
Max Age
60 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2003-07-31
Primary Completion
2004-07-31
Completion
2005-07-31

Countries

  • Germany

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT00266526 on ClinicalTrials.gov